Eli Lilly’s Zepbound holds possibility to dominate obesity market GlobalData Dec 31, 2024 Recently, Eli Lilly announced the results from its SURMOUNT-5 trial, comparing Zepbound and Wegovy’s efficacy on equal grounds
GLP-1R market: A two-horse race, says GlobalData GlobalData Aug 21, 2024 As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase…
